Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heron Therapeutics, Inc. on July 2, 2024. The report discloses a material event regarding the regulatory status of the Company's product, ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory update and does not contain financial statement data.
Material Changes
- Regulatory Update: The U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company's Prior Approval Supplement application for ZYNRELEF®.
- Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 23, 2024, for the review of this application.
Outlook, Risks, and Management Commentary
Management has announced the receipt acknowledgment via a press release (Exhibit 99.1). The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. No specific financial guidance, risk factors, or contingencies beyond the standard regulatory review process are detailed in this specific document.
Investor Verification Checklist
- Verify the specific details of the Prior Approval Supplement application for ZYNRELEF® in the attached press release (Exhibit 99.1).
- Monitor the FDA's decision status leading up to the September 23, 2024, PDUFA goal date.
- Review subsequent filings for any updates on the approval outcome or potential delays.